Sexually Transmitted Infections: Human Papillomavirus Vaccine

Merck’s recently released vaccine, Gardasil, may revolutionize cervical cancer prevention. With the rate of detected cervical cancer cases and associated deaths rising rapidly, cervical cancer is a major public health concern. Infection with the human papillomavirus, a sexually transmitted disease, is a necessary cause of cervical cancer. Gardasil protects against two specific “high risk” strains of HPV, associated with about 70% of cervical cancer cases, and blocks infection by two other strains of HPV, responsible for 90% of genital warts cases. Proponents of Gardasil believe that vaccination of women between the ages of 12 and 26 can slow the spread of cervical cancer by eradicating the two major HPV strands associated with the cancer’s development.

Download Full-text

Para - And Intraurethral Penile Tumor - Like Condylomatosis

Open Access Macedonian Journal of Medical Sciences ◽

10.3889/oamjms.2018.007 ◽

2018 ◽

Vol 6 (1) ◽

pp. 110-111

Author(s):

Anastasiya Atanasova Chokoeva ◽

Uwe Wollina ◽

Torello Lotti ◽

Georgi Konstantinov Maximov ◽

Ilia Lozev ◽

...

Keyword(s):

Human Papillomavirus ◽

Treatment Options ◽

Transmitted Disease ◽

Condylomata Acuminata ◽

Human Papillomavirus Vaccine ◽

Virus Eradication ◽

Oncogenic Potential ◽

Sexually Transmitted ◽

Papillomavirus Vaccine ◽

Further Development

Condyloma acuminata represents an epidermal manifestation, associated with the epidermotropic human papillomavirus (HPV). They have been reported as the most common sexually transmitted disease, with prevalence exceeding 50%, increased up to 4 times, within the last two decades, as the most common side of affection are the penis, vulva, vagina, cervix, perineum, and perianal area, with increased prevalence in young, sexually active individuals. Increased attention should be focused on lesions, caused by types, with moderate (33, 35, 39, 40, 43, 45, 51-56, 58) or high risk potential (types 16, 18) for malignant transformation, leading to further development of cancers of anus, vagina, vulva and penis, as well as cancers of the head and neck . A provident of coexistence of many of these types in the same patient could be seen in approximately 10-15% of patients, as the lack of adequate information on the oncogenic potential of many other types complicated the treatment and the further outcome. Although the variety of treatment options, genital condylomata acuminata still show high recurrent rate to destructive topical regiments, because of the activation of the viruses at some point, which emphasise the importance of virus- eradication, instead only of the topical destruction of the lesions. Despite decreasing the recurrent rate, the most important goal of immunisation is the reduction of the incidence of HPV-associated squamous cell carcinomas using either the quadrivalent (Silgard/Gardasil) or the bivalent (Cervarix) HPV (human papillomavirus) vaccine. We present a patient with periurethral condylomata acuminate, who refused performing of a biopsy for determining the virus type, as we want to emphasize the importance of the virus - treatment in all cases of genital warts, instead only of topical destruction of the lesions, not only because of the recurrence incidence rate, but also because of the well - known oncogenic potential of some HPV - types, as well as the unknown potential of various underestimated types, in contrast.

Download Full-text

First-Generation Vaccines against Human Papillomavirus

Women s Health ◽

10.2217/17455057.1.2.223 ◽

2005 ◽

Vol 1 (2) ◽

pp. 223-229

Author(s):

Jorma Paavonen ◽

Matti Lehtinen

Keyword(s):

Human Papillomavirus ◽

Sexually Transmitted Infection ◽

First Generation ◽

Preclinical Studies ◽

Human Papillomavirus Vaccine ◽

Transmitted Infection ◽

Vaccine Candidates ◽

Sexually Transmitted ◽

The Past ◽

Papillomavirus Vaccine

There has been considerable progress in the development of a prophylactic human papillomavirus vaccine in the past 10 years, since the discovery of human papillomavirus virus-like particles. Licensure of the human papillomavirus vaccine is probably not far away. This would make it the first licensed vaccine against a common sexually transmitted infection. Although hepatitis B is a sexually transmitted infection for which there is an effective prophylactic vaccine, it is often not perceived as such by individuals taking the vaccine. Preclinical studies have already produced attractive vaccine candidates and recent clinical trials have yielded strikingly promising results. The candidate vaccines are generally well tolerated, induce high titers of serum antibodies to the human papillomavirus types and effectively prevent acquisition of infection and early clinical disease caused by common human papillomavirus types.

Download Full-text

Human medicines European public assessment report (EPAR): Cervarix, human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed), Papillomavirus Infections,Uterine Cervical Dysplasia,Immunization, Date of authorisation: 20/09/2007, Revision: 32, Status: Authorised

Case Medical Research ◽

10.31525/cmr-145d596 ◽

2019 ◽

Author(s):

Keyword(s):

Human Papillomavirus ◽

Cervical Dysplasia ◽

Human Papillomavirus Vaccine ◽

Papillomavirus Infections ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Papillomavirus Vaccine ◽

Uterine Cervical Dysplasia

Download Full-text

Faculty Opinions recommendation of Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3334958.3023056 ◽

2010 ◽

Author(s):

Megan Huchko

Keyword(s):

Human Papillomavirus ◽

Sexually Transmitted Infections ◽

Sexually Transmitted ◽

Human Papillomavirus Infection ◽

Papillomavirus Infection ◽

Hiv Acquisition ◽

Risk Of Hiv Acquisition

Download Full-text

Vaccine Hesitancy and Differential Susceptibility to Media Coverage: A Critical Documentary Led to Substantial Reductions in Human Papillomavirus Vaccine Uptake in Denmark

Medical Decision Making ◽

10.1177/0272989x211003589 ◽

2021 ◽

pp. 0272989X2110035

Author(s):

Maria Knoth Humlum ◽

Niels Skipper ◽

Peter Rønø Thingholm

Keyword(s):

Human Papillomavirus ◽

Hpv Vaccine ◽

Media Coverage ◽

Differential Susceptibility ◽

Vaccine Uptake ◽

Vaccine Hesitancy ◽

Human Papillomavirus Vaccine ◽

Policy Makers ◽

Quasi Experimental ◽

Papillomavirus Vaccine

Objectives To investigate whether negative media coverage of the human papillomavirus (HPV) vaccine led to a decrease in the uptake of the first dose of the HPV vaccine (HPV1) in Denmark and, importantly, whether some groups of individuals were more susceptible to negative media coverage. Methods We measured HPV vaccine uptake of 12-year-old girls born in 2001 to 2004 using Danish administrative data. A quasi-experimental design was employed to assess whether a documentary that was critical of the HPV vaccine and aired in March 2015 affected HPV uptake. Results The documentary led to a quick and substantial decrease in the monthly propensity to vaccinate, which dropped 3 percentage points—or about 50%—in response to the documentary. Responses differed substantially across subgroups, and girls from families with high socioeconomic status (SES) were more susceptible to the negative media coverage. Conclusions Susceptibility to negative media coverage varied substantially across subgroups, highlighting the need for policy makers to appropriately target and differentiate initiatives to improve vaccine compliance rates.

Download Full-text